- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07236034
ARISe at UMass Chan (ARISe)
ARISe at UMass Chan: Remote Eye Tracking Study of Vaccine Messaging in Rural Populations
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Grace W Ryan, PhD, MPH
- Phone Number: 508-859-0179
- Email: grace.ryan1@umassmed.edu
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01605
- Recruiting
- University of Massachusetts Chan Medical School
-
Contact:
- Grace Assistant Professor, PhD, MPH
- Phone Number: 508-859-0179
- Email: arise@umassmed.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18+
- Living in New England state (CT, MA, ME, NH, VT RI) in a zip code as defined by each individual state's definition of rural
- Able to read and write in English
- Access to an internet connected computer or laptop with a web-camera
Exclusion Criteria:
- N/A
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm 1: Peer message, 7C Construct 1
This arm will include messages with a "peer" influence as the source and the construct of "confidence" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 2: Professional source, 7C Construct 1
This arm will include messages with a "professional" influencer as the source and the construct of "confidence" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 3: Peer message, 7C Construct 2
This arm will include messages with a "peer" influence as the source and the construct of "complacency" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 4: Professional message, 7C Construct 2
This arm will include messages with a "professional" influence as the source and the construct of "complacency" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 5: Peer message, 7C Construct 3
This arm will include messages with a "peer" influence as the source and the construct of "constraints" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 6: Professional message, 7C Construct 3
This arm will include messages with a "professional" influencer as the source and the construct of "constraints" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 7: Peer message, 7C Construct 4
This arm will include messages with a "peer" influencer as the source and the construct of "calculation" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 8: Professional message, 7C Construct 4
This arm will include messages with a "professional" influencer as the source and the construct of "calculation" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 9: Peer message, 7C Construct 5
This arm will include messages with a "peer" influencer as the source and the construct of "collective responsibility" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 10: Professional message, 7C Construct 5
This arm will include messages with a "professional" influencer as the source and the construct of "collective responsibility" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 11: Peer message; 7C Construct 6
This arm will include messages with a "peer" influencer as the source and the construct of "compliance" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 12: Professional message, 7C Construct 6
This arm will include messages with a "professional" influencer as the source and the construct of "compliance" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 13: Peer message, 7C Construct 7
This arm will include messages with a "peer" influencer as the source and the construct of "conspiracy" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
|
Experimental: Arm 14: Professional message, 7C Construct 7
This arm will include messages with a "professional" influencer as the source and the construct of "conspiracy" as the message.
|
Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Source credibility
Time Frame: Immediately after viewing each message
|
Participants' perception of the credibility of the message source will be assessed using a 7-point Likert scale measured across four items. Participants will be asked to rate the following four items on this scale: To what extent do you believe the source of the message to be… (1=not at all, 7=very much so)
Unit of measure: Scale score 1-7, mean |
Immediately after viewing each message
|
|
Perceived Message Effectiveness
Time Frame: Immediately after viewing each message
|
Perceived message effectiveness will be measured using six items (worth remembering, grabs attention, powerful, informative, meaningful, convincing), each rated on a 7-point Likert scale. The outcome will be the mean of these six ratings for each participant, then averaged by experimental condition. To what extent is… (1=not at all, 7=very much so)
|
Immediately after viewing each message
|
|
Visual attention
Time Frame: During message viewing ( immediately post-randomization, prior to completion of post-message survey)
|
Visual attention, quantified as mean dwell time in milliseconds, will be measured using remote eye-tracking while participants view vaccine promotion messages. Dwell time will be calculated for pre-specified Areas of Interest (AOIs) during the message viewing period. Higher dwell times indicate greater visual attention to the AOIs. Unit of measure: mean dwell time in milliseconds per message |
During message viewing ( immediately post-randomization, prior to completion of post-message survey)
|
|
Message reactance
Time Frame: Immediately after viewing each message
|
Reactance will be assessed using four items (irritated, angry, annoyed, aggravated), rated 0 ("None of this feeling") to 4 ("A great deal of this feeling"). The mean reactance score will be calculated for each participant. How much did this message make you feel the following way? Response options: 0 (None of this feeling) to 4 (A great deal of this feeling).
Unit of Measure: Scale score (0-4, mean across items) |
Immediately after viewing each message
|
|
Information sharing intentions
Time Frame: Immediately after viewing each message
|
Description: Assessed with 6 items regarding interpersonal and online sharing, rated 1 (Strongly disagree) to 5 (Strongly agree). The mean score across items will be reported per participant and per condition. Rate with the following statements on a scale from 1 (Strongly disagree) to 5 (Strongly agree). Interpersonal setting
Unit of Measure: Scale score (1-5, mean across items) |
Immediately after viewing each message
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vaccine perceptions
Time Frame: Assessed at baseline (prior to message exposure) and immediately post-intervention (after message exposure)
|
Vaccine perceptions will be measured using an 8-item scale, administered pre- and post-message exposure. Items are rated from 1 (Strongly disagree/very negative) to 7 (Strongly agree/very positive). Higher scores indicate more positive vaccine perceptions. The outcome will be the mean change in score from pre- to post-exposure. Unit of Measure: Scale score (1-7, mean change) |
Assessed at baseline (prior to message exposure) and immediately post-intervention (after message exposure)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Grace W Ryan, PhD, MPH, University of Massachusetts Chan Medical School
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- STUDY00002075
- 1U48DP006883-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaccination
-
University of TorontoWholehealth Pharmacy PartnersNot yet recruitingVaccination | Vaccination Reaction | Vaccination Pain | Vaccination PharmacyCanada
-
University of IowaNational Institute on Aging (NIA)CompletedVaccination | Vaccination Hesitancy | Vaccination Promotion | Psychological AspectsUnited States
-
University of Roma La SapienzaCompletedVaccination Failure | Vaccination Adverse Events | Specific Antibody ResponseItaly
-
Xiamen UniversityXiamen Center for Disease Control and PreventionNot yet recruitingHPV Vaccination Rates | HPV Vaccine Awareness | HPV Vaccination Intention
-
National Cancer Institute (NCI)CompletedHPV16 Anitbody Levels Post Vaccination | HPV18 Antibody Levels Post VaccinationUganda
-
University of PennsylvaniaCompletedVaccine Refusal | Vaccination Hesitancy | Human Papillomavirus VaccinationUnited States
-
Université de Reims Champagne-ArdenneRecruiting
-
University of EssexUniversity of Southern California; Kingston University; Department of Health...Completed
-
China National Biotec Group Company LimitedPeking University; Beijing Institute of Biological Products Co Ltd.; Sichuan... and other collaboratorsCompleted
-
China National Biotec Group Company LimitedSichuan Center for Disease Control and PreventionCompleted
Clinical Trials on Exposure to source and message content
-
University of North Carolina, Chapel HillDuke University; Stanford UniversityCompleted
-
University of ManitobaCanadian Immunization Research NetworkCompleted
-
University of GeorgiaRecruitingMessage Exposure (Sequence: Regular Then Flavor) | Message Exposure (Sequence: Flavor Then Regular) | No Message Exposure (Control Condition)United States
-
Hôpital le VinatierCompleted
-
Clinical Research Centre, MalaysiaUniversity of Malaya; London School of Economics and Political Science; Ministry... and other collaboratorsCompletedCoronavirus Infections | Respiratory Tract Infections | COVID-19 | Pneumonia, Viral | Pneumonia | Lung Diseases | Infectious Disease | Respiratory Disease | Behavior, Health | Vaccine RefusalMalaysia
-
Imperial College LondonImperial College Healthcare NHS TrustCompletedBehavioural Science Interventions to Improve Health EquityUnited Kingdom
-
Georgia State UniversityCompletedSmoking | Risk Behavior | Smoking, Tobacco | Smoking Behaviors | Health CommunicationUnited States
-
University of LouisvilleWithdrawnDiabetes Mellitus, Type 1United States
-
Cosmetique Active InternationalCompletedStudy the Potency of Sunscreen to Protect Against the Pigmentation Induced by Visible Light Exposure on Healthy Back SkinFrance
-
Centers for Disease Control and PreventionMalaria Alert CentreCompletedPneumonia | Diarrhea | Malaria